1. Please check and comment entries here.
Table of Contents

    Topic review

    Primary Central Nervous System Lymphoma

    Subjects: Oncology
    View times: 8

    Definition

    Primary central nervous system lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma confined to the central nervous system (CNS) and mainly affects elderly patients.

    1. Introduction

    Studies carried out with different nationwide population cohorts have revealed an increased incidence among elderly patients over time, both overall and in the immunocompetent subgroup [1][2][3][4][5]. Large population studies in the United States have shown an increase in the PCNSL rate of 1.7% per year in people older than 65 years (with stable rates in other age groups) during the period 1992–2011 [1] and an increase in the incidence, from 0.2 in 1973 to 2.1 per 100,000 in 2013, in people older than 70 years [3]. In addition, a population-based study in Sweden revealed an increased incidence, from 0.43 to 1.66 per 100,000 habitants among patients aged 70 and older between 2000–2002 and 2012–2013 [2]. A nationwide population-based study reported an overall increase among PCNSL patients diagnosed in the Netherlands between 1989 and 2015 as a result of the increasing incidence in the group older than 60 years, exhibiting a twofold increase in PCNSL incidence during this period [4]. This increase remains largely unexplained even though it may be partially due to the global aging of the population, longer life expectancy and advances in diagnostic techniques and approaches.

    PCNSL overall survival (OS) has steadily improved for the youngest patients. In contrast, despite advances in the management of the older population, the prognosis of elderly patients remains poor [2][3][4][6]. An American nationwide report showed that PCNSL survival has not improved for patients older than 70 years since the 1970s, remaining at approximately 6–7 months, even though the median OS of all patients doubled in the same period [3]. However, the results from nationwide reports include patients treated only with palliative care, a common situation for elderly individuals, which is not always reported. A Dutch nationwide population-based study revealed that, while the use of chemotherapy has progressively increased in elderly patients up to age 70 years, with a consequent improvement in OS, approximately 40% of patients older than 70 years did not receive antineoplastic therapy, exhibiting poor prognosis [4]. A systematic review and meta-analysis by Kasenda et al. of 783 elderly patients diagnosed with and treated for PCNSL from 1977 to 2014 revealed a progressive OS improvement over time [6].

    Regarding 1st line treatment, elderly patients are more often untreated or less vigorously treated than younger patients [4][7][8][9][10]. Altogether, physiological status related to age, higher rate of comorbidities and differences in therapeutic management may contribute to the poorer prognosis in elderly patients with PCNSL and warrant to be better investigated and taken into account, in order to optimize management strategies and tolerance and improve outcomes.

    2. Clinical Aspects

    Functional status at the time of diagnosis, an independent prognostic factor in PCNSL [11][12][13], is usually lower in elderly patients than it is in younger patients [7][9]. Clinical manifestations in elderly patients are similar to those in younger patients, including focal neurological deficits, neurocognitive and/or behavior changes, symptoms of increased intracranial pressure and, less frequently, epilepsy. However, elderly patients display a higher proportion of cognitive impairments at diagnosis than those in other age groups [7][9][14]. Unpublished data from the French LOC network study show a higher proportion of cognitive impairments at the time of diagnosis in patients older than 60 years (65% versus 48%, p < 0.001). In elderly patients, cognitive symptoms could be inaccurately attributed or associated with other prevalent pathologies in this age group (such as vascular or degenerative diseases), increasing the delay in diagnosis [14] and affecting the prognosis [9][15][16]. In addition, neurocognitive dysfunction at diagnosis was recently reported as an independent prognostic factor [17][18].

    Older age is also associated with a higher frequency of comorbidities, which may increase the risk of therapy-induced toxicity that alters the pharmacokinetics and pharmacodynamics of therapy and may increase the risk of toxicities. However, as discussed below, elderly patients with PCNSL can achieve a response even to more intense treatments, so they should not be excluded from these therapies only on the basis of age criteria, but rather on the basis of a global assessment for fitness. Nevertheless, this approach is still very scarce. In a pilot study, Schorb et al. have utilized the Cumulative Illness Rating Scale–Geriatric score as an inclusion criterion in addition to age [19]. Such approaches should be developed.

    3. Diagnosis

    The PCNSL diagnostic approach in the elderly population is similar to that of other age groups. Histopathological confirmation by cerebral stereotactic biopsy or positive cytology in the CSF or vitreous biopsy sample is required to establish the diagnosis before starting treatment and should be obtained without delay [20][21]. Because steroids may induce rapid tumor shrinkage [22][23][24][25][26][27], their use before brain biopsy should be delayed as much as possible as it may prevent pathological confirmation [20][21].

    Stereotactic biopsy is considered a safe high-yield diagnostic procedure in PCNSL [28], even in elderly patients and in cases of deep lesions that are quite common [29][30][31]. However, elderly patients present more frequently with deteriorated functional status and/or the presence of multiple comorbidities, preventing the use of biopsy to obtain samples. In these situations, a noninvasive diagnostic tool with high sensitivity and specificity would be useful.

    In the past decade, several biomarkers measured in the CSF and the vitreous (in the case of vitreoretinal involvement) were investigated as potentially useful for the diagnosis of PCNSL, such as IL-10, IL-6, CXCL13, miRNA 19-21-92a , neopterin, CD19, and MYD88 hotspot mutations [32][33][34][35][36][37][38][39][40][41][42][43][44][45]. Although biopsy remains the gold standard for diagnosis, the increase in the CSF IL-10 level and CSF IL-10/IL-6 ratio, with sensitivities ranging from 60 to 97% and specificities ranging from 90 to 100% [38][39][40][41][42], are helpful tools for diagnostic guidance, especially in atypical radiological presentations and when performing a biopsy is not feasible. Preliminary results also suggest their potential predictive role in posttreatment evaluation for monitoring treatment responses [40]. A combined analysis of MYD88 mutation and IL-10 level in the CSF was reported with a sensitivity and specificity of 94% and 98%, respectively, in newly diagnosed PCNSL [45].

    4. Treatment

    A retrospective study devoted to elderly patients failed to show a clear benefit of extending cytarabine consolidation treatment after methotrexate-based chemotherapy (R-MPV regimen consolidated with three cycles of high-dose cytarabine instead of one) but was associated with increased toxicity in elderly patients [46].

    Recent advances in DLBCL have been used to evaluate the activity of innovative agents in PCNSL, mainly in refractory/relapsing (R/R) tumors, with notably targeted therapies and immunotherapy, such as imids [47][48][49][50][51][52], ibrutinib [53][54][55][56] and anti-PD-1 [57][58][59]. As these novel agents demonstrate promising efficacy in term of objective response rate and good safety profiles in clinical trials or retrospective studies without limitation of age they are excellent candidates to be incorporated in 1st line induction and/or maintenance treatment in the near future and could benefit elderly patients.

    These reports show that HD-MTX is also a feasible and active treatment in the oldest patients but requires adapted doses according to urinary clearance and comorbidities. For patients unfit for HD-MTX treatment, due to impaired renal function or other comorbidities, temozolomide chemotherapy may be a treatment option. In a series of 17 elderly patients (6 in the oldest group) treated with temozolomide monotherapy as 1st line therapy, 29.4% had prolonged responses for at least 12 months and survived for more than 24 months with good tolerance [60].

    WBRT alone can also be considered as a therapeutic option in the first-line for unfit patients and induces a high response rate. However, responses are most often of short duration [61] and given the high risk of neurotoxicity in elderly patients, we rather recommend chemotherapy options in this setting.

    The entry is from 10.3390/cancers13143479

    References

    1. Shiels, M.S.; Pfeiffer, R.M.; Besson, C.; Clarke, C.A.; Morton, L.M.; Nogueira, L.; Pawlish, K.; Yanik, E.L.; Suneja, G.; Engels, E.A. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br. J. Haematol. 2016, 174, 417–424.
    2. Eloranta, S.; Brånvall, E.; Celsing, F.; Papworth, K.; Ljungqvist, M.; Enblad, G.; Ekström-Smedby, K. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000–2013. Eur. J. Haematol. 2018, 100, 61–68.
    3. Mendez, J.S.; Ostrom, Q.T.; Gittleman, H.; Kruchko, C.; DeAngelis, L.M.; Barnholtz-Sloan, J.S.; Grommes, C. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro. Oncol. 2018, 20, 687–694.
    4. Van der Meulen, M.; Dinmohamed, A.G.; Visser, O.; Doorduijn, J.K.; Bromberg, J.E.C. Improved survival in primary central nervous system lymphoma up to age 70 only: A population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015. Leukemia 2017, 31, 1822–1825.
    5. Villano, J.L.; Koshy, M.; Shaikh, H.; Dolecek, T.A.; McCarthy, B.J. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br. J. Cancer. 2011, 105, 1414–1418.
    6. Kasenda, B.; Ferreri, A.J.; Marturano, E.; Forst, D.; Bromberg, J.; Ghesquieres, H.; Ferlay, C.; Blay, J.Y.; Hoang-Xuan, K.; Pulczynski, E.J.; et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—A systematic review and individual patient data meta-analysis. Ann. Oncol. 2015, 26, 1305–1313.
    7. Houillier, C.; Soussain, C.; Ghesquières, H.; Soubeyran, P.; Chinot, O.; Taillandier, L.; Lamy, T.; Choquet, S.; Ahle, G.; Damaj, G.; et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology 2020, 94, e1027–e1039.
    8. Roth, P.; Martus, P.; Kiewe, P.; Möhle, R.; Klasen, H.; Rauch, M.; Röth, A.; Kaun, S.; Thiel, E.; Korfel, A.; et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 2012, 79, 890–896.
    9. Velasco, R.; Mercadal, S.; Vidal, N.; Alañá, M.; Barceló, M.I.; Ibáñez-Juliá, M.J.; Bobillo, S.; Caldú-Agud, R.; García-Molina, E.; Martínez, P.; et al. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: A multicentric study. J. Neurooncol. 2020, 148, 545–554.
    10. Ney, D.E.; Reiner, A.S.; Panageas, K.S.; Brown, H.S.; DeAngelis, L.M.; Abrey, L.E. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center experience. Cancer 2010, 116, 4605–4612.
    11. Ferreri, A.J.; Blay, J.Y.; Reni, M.; Pasini, F.; Spina, M.; Ambrosetti, A.; Calderoni, A.; Rossi, A.; Vavassori, V.; Conconi, A.; et al. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J. Clin. Oncol. 2003, 21, 266–272.
    12. Abrey, L.E.; Ben-Porat, L.; Panageas, K.S.; Yahalom, J.; Berkey, B.; Curran, W.; Schultz, C.; Leibel, S.; Nelson, D.; Mehta, M.; et al. Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model. J. Clin. Oncol. 2006, 24, 5711–5715.
    13. Ahn, Y.; Ahn, H.J.; Yoon, D.H.; Hong, J.Y.; Yoo, C.; Kim, S.; Huh, J.; Suh, C. Primary central nervous system lymphoma: A new prognostic model for patients with diffuse large B-cell histology. Blood Res. 2017, 52, 285–292.
    14. Welch, M.R.; Omuro, A.; Deangelis, L.M. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro. Oncol. 2012, 14, 1304–1311.
    15. Cerqua, R.; Balestrini, S.; Perozzi, C.; Cameriere, V.; Renzi, S.; Lagalla, G.; Mancini, G.; Montanari, M.; Leoni, P.; Scerrati, M.; et al. Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme. Neurol. Sci. 2016, 37, 23–29.
    16. Laude, M.C.; Julia, E.; Nicolas-Virelizier, E.; Antherieu, G.; Safar, V.; Rey, P.; Ferrant, E.; Traverse-Glehen, A.; Chassagne-Clément, C.; Meyronet, D.; et al. Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma. Blood 2020, 136 (Suppl. 1), 43–45.
    17. Omuro, A.; Chinot, O.; Taillandier, L.; Ghesquieres, H.; Soussain, C.; Delwail, V.; Lamy, T.; Gressin, R.; Choquet, S.; Soubeyran, P.; et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: An intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015, 2, e251–e259.
    18. Van der Meulen, M.; Dirven, L.; Bakunina, K.; van den Bent, M.J.; Issa, S.; Doorduijn, J.K.; Bromberg, J.E.C. MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma. J. Neurooncol. 2021, 152, 357–362.
    19. Schorb, E.; Kasenda, B.; Ihorst, G.; Scherer, F.; Wendler, J.; Isbell, L.; Fricker, H.; Finke, J.; Illerhaus, G. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: A pilot study. Blood Adv. 2020, 4, 3378–3381.
    20. Hoang-Xuan, K.; Bessell, E.; Bromberg, J.; Hottinger, A.F.; Preusser, M.; Rudà, R.; Schlegel, U.; Siegal, T.; Soussain, C.; Abacioglu, U.; et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: Guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015, 16, e322–e332.
    21. Fox, C.P.; Phillips, E.H.; Smith, J.; Linton, K.; Gallop-Evans, E.; Hemmaway, C.; Auer, D.P.; Fuller, C.; Davies, A.J.; McKay, P.; et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br. J. Haematol. 2019, 184, 348–363.
    22. Burton, A.F.; Storr, J.M.; Dunn, W.L. Cytolytic action of corticosteroids on thymus and lymphoma cells in vitro. Can. J. Biochem. 1967, 45, 289–297.
    23. Helmberg, A.; Auphan, N.; Caelles, C.; Karin, M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J. 1995, 14, 452–460.
    24. Ayroldi, E.; Zollo, O.; Bastianelli, A.; Marchetti, C.; Agostini, M.; Di Virgilio, R.; Riccardi, C. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J. Clin. Investig. 2007, 117, 1605–1615.
    25. Roth, P.; Wick, W.; Weller, M. Steroids in neurooncology: Actions, indications, side-effects. Curr. Opin. Neurol. 2010, 23, 597–602.
    26. Grander, D.; Kharaziha, P.; Laane, E.; Pokrovskaja, K.; Panaretakis, T. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy 2009, 5, 1198–1200.
    27. Laane, E.; Tamm, K.P.; Buentke, E.; Ito, K.; Kharaziha, P.; Oscarsson, J.; Corcoran, M.; Björklund, A.C.; Hultenby, K.; Lundin, J.; et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ. 2009, 16, 1018–1029.
    28. McGirt, M.J.; Woodworth, G.F.; Coon, A.L.; Frazier, J.M.; Amundson, E.; Garonzik, I.; Olivi, A.; Weingart, J.D. Independent predictors of morbidity after image-guided stereotactic brain biopsy: A risk assessment of 270 cases. J. Neurosurg. 2005, 102, 897–901.
    29. Malikova, H.; Liscak, R.; Latnerova, I.; Guseynova, K.; Syrucek, M.; Pytlik, R. Complications of MRI-guided stereotactic biopsy of brain lymphoma. Neuro. Endocrinol. Lett. 2014, 35, 613–618.
    30. Morell, A.A.; Shah, A.H.; Cavallo, C.; Eichberg, D.G.; Sarkiss, C.A.; Benveniste, R.; Ivan, M.E.; Komotar, R.J. Diagnosis of primary central nervous system lymphoma: A systematic review of the utility of CSF screening and the role of early brain biopsy. Neurooncol. Pract. 2019, 6, 415–423.
    31. Kellermann, S.G.; Hamisch, C.A.; Rueß, D.; Blau, T.; Goldbrunner, R.; Treuer, H.; Grau, S.J.; Ruge, M.I. Stereotactic biopsy in elderly patients: Risk assessment and impact on treatment decision. J. Neurooncol. 2017, 134, 303–307.
    32. Rubenstein, J.; Wong, V.; Kadoch, C.; Gao, H.X.; Barajas, R.; Chen, L.; Josephson, A.; Scott, B.; Douglas, V.; Maiti, M.; et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 2013, 121, 4740–4748.
    33. Baraniskin, A.; Kuhnhenn, J.; Schlegel, U.; Chan, A.; Deckert, M.; Gold, R.; Maghnouj, A.; Zöllner, H.; Reinacher-Schick, A.; Schmiegel, W.; et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011, 117, 3140–3146.
    34. Viaccoz, A.; Ducray, F.; Tholance, Y.; Barcelos, G.K.; Thomas-Maisonneuve, L.; Ghesquières, H.; Meyronet, D.; Quadrio, I.; Cartalat-Carel, S.; Louis-Tisserand, G.; et al. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro. Oncol. 2015, 17, 1497–1503.
    35. Muñiz, C.; Martín-Martín, L.; López, A.; Sánchez-González, B.; Salar, A.; Almeida, J.; Sancho, J.M.; Ribera, J.M.; Heras, C.; Peñalver, F.J.; et al. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. Blood 2014, 123, 1864–1869.
    36. Poulain, S.; Boyle, E.M.; Roumier, C.; Demarquette, H.; Wemeau, M.; Geffroy, S.; Herbaux, C.; Bertrand, E.; Hivert, B.; Terriou, L.; et al. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br. J. Haematol. 2014, 167, 506–513.
    37. Hiemcke-Jiwa, L.S.; Minnema, M.C.; Radersma-van Loon, J.H.; Jiwa, N.M.; de Boer, M.; Leguit, R.J.; de Weger, R.A.; Huibers, M.M.H. The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol. Oncol. 2018, 36, 429–435.
    38. Geng, M.; Song, Y.; Xiao, H.; Wu, Z.; Deng, X.; Chen, C.; Wang, G. Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma. Oncol. Lett. 2021, 21, 2.
    39. Shao, J.; Chen, K.; Li, Q.; Ma, J.; Ma, Y.; Lin, Z.; Kang, H.; Chen, B. High Level of IL-10 in Cerebrospinal Fluid is Specific for Diagnosis of Primary Central Nervous System Lymphoma. Cancer Manag. Res. 2020, 12, 6261–6268.
    40. Nguyen-Them, L.; Costopoulos, M.; Tanguy, M.L.; Houillier, C.; Choquet, S.; Benanni, H.; Elias-Shamieh, R.; Armand, M.; Faivre, G.; Glaisner, S.; et al. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur. J. Cancer 2016, 61, 69–76.
    41. Song, Y.; Zhang, W.; Zhang, L.; Wu, W.; Zhang, Y.; Han, X.; Yang, C.; Zhang, L.; Zhou, D. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma. Sci. Rep. 2016, 6, 38671.
    42. Sasayama, T.; Nakamizo, S.; Nishihara, M.; Kawamura, A.; Tanaka, H.; Mizukawa, K.; Miyake, S.; Taniguchi, M.; Hosoda, K.; Kohmura, E. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro. Oncol. 2012, 14, 368–380.
    43. Hiemcke-Jiwa, L.S.; Ten Dam-van Loon, N.H.; Leguit, R.J.; Nierkens, S.; Ossewaarde-van Norel, J.; de Boer, J.H.; Roholl, F.F.; de Weger, R.A.; Huibers, M.M.H.; de Groot-Mijnes, J.D.F.; et al. Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction. JAMA Ophthalmol. 2018, 136, 1098–1104.
    44. Yonese, I.; Takase, H.; Yoshimori, M.; Onozawa, E.; Tsuzura, A.; Miki, T.; Mochizuki, M.; Miura, O.; Arai, A. CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential. Eur. J. Haematol. 2019, 102, 191–196.
    45. Ferreri, A.J.M.; Calimeri, T.; Lopedote, P.; Francaviglia, I.; Daverio, R.; Iacona, C.; Belloni, C.; Steffanoni, S.; Gulino, A.; Anghileri, E.; et al. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: Results from a prospective study. Br. J. Haematol. 2021, 193, 497–505.
    46. Houillier, C.; Ghesquières, H.; Chabrot, C.; Soussain, C.; Ahle, G.; Choquet, S.; Nicolas-Virelizier, E.; Bay, J.O.; Vargaftig, J.; Gaultier, C.; et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: A LOC network study. J. Neurooncol. 2017, 133, 315–320.
    47. Lopez-Girona, A.; Mendy, D.; Ito, T.; Miller, K.; Gandhi, A.K.; Kang, J.; Karasawa, S.; Carmel, G.; Jackson, P.; Abbasian, M.; et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012, 26, 2326–2335.
    48. Gribben, J.G.; Fowler, N.; Morschhauser, F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J. Clin. Oncol. 2015, 33, 2803–2811.
    49. Houillier, C.; Choquet, S.; Touitou, V.; Martin-Duverneuil, N.; Navarro, S.; Mokhtari, K.; Soussain, C.; Hoang-Xuan, K. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology 2015, 84, 325–326.
    50. Rubenstein, J.L.; Geng, H.; Fraser, E.J.; Formaker, P.; Chen, L.; Sharma, J.; Killea, P.; Choi, K.; Ventura, J.; Kurhanewicz, J.; et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018, 2, 1595–1607.
    51. Ghesquieres, H.; Chevrier, M.; Laadhari, M.; Chinot, O.; Choquet, S.; Moluçon-Chabrot, C.; Beauchesne, P.; Gressin, R.; Morschhauser, F.; Schmitt, A.; et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: A multicenter prospective ‘proof of concept’ phase II study of the french oculo-cerebral lymphoma (LOC) network and the lymphoma study association (LYSA) dagger. Ann. Oncol. 2019, 30, 621–628.
    52. Tun, H.W.; Johnston, P.B.; DeAngelis, L.M.; Atherton, P.J.; Pederson, L.D.; Koenig, P.A.; Reeder, C.B.; Omuro, A.M.P.; Schiff, D.; O’Neill, B.; et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood 2018, 132, 2240–2248.
    53. Lionakis, M.S.; Dunleavy, K.; Roschewski, M.; Widemann, B.C.; Butman, J.A.; Schmitz, R.; Yang, Y.; Cole, D.E.; Melani, C.; Higham, C.S.; et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell 2017, 31, 833–843.e5.
    54. Grommes, C.; Pastore, A.; Palaskas, N.; Tang, S.S.; Campos, C.; Schartz, D.; Codega, P.; Nichol, D.; Clark, O.; Hsieh, W.Y.; et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017, 7, 1018–1029.
    55. Soussain, C.; Choquet, S.; Blonski, M.; Leclercq, D.; Houillier, C.; Rezai, K.; Bijou, F.; Houot, R.; Boyle, E.; Gressin, R.; et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur. J. Cancer 2019, 117, 121–130.
    56. Grommes, C.; Tang, S.S.; Wolfe, J.; Kaley, T.J.; Daras, M.; Pentsova, E.I.; Piotrowski, A.F.; Stone, J.; Lin, A.; Nolan, C.P.; et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood 2019, 133, 436–445.
    57. Nayak, L.; Iwamoto, F.M.; LaCasce, A.; Mukundan, S.; Roemer, M.G.M.; Chapuy, B.; Armand, P.; Rodig, S.J.; Shipp, M.A. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 2017, 129, 3071–3073.
    58. Ambady, P.; Szidonya, L.; Firkins, J.; James, J.; Johansson, K.; White, T.; Jezierski, C.; Doolittle, N.D.; Neuwelt, E.A. Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk. Lymphoma 2019, 60, 515–518.
    59. Hoang-Xuan, K.; Houot, R.; Soussain, C.; Blonski, M.; Schmitt, A.; Delwail, V.; Damaj, G.L.; Ghesquieres, H.; Peyrade, F.; Tempescul, A.; et al. First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort. Blood 2020, 136 (Suppl. 1), 15–16.
    60. Kurzwelly, D.; Glas, M.; Roth, P.; Weimann, E.; Lohner, H.; Waha, A.; Schabet, M.; Reifenberger, G.; Weller, M.; Herrlinger, U. Primary CNS lymphoma in the elderly: Temozolomide therapy and MGMT status. J. Neurooncol. 2010, 97, 389–392.
    61. Nelson, D.F.; Martz, K.L.; Bonner, H.; Nelson, J.S.; Newall, J.; Kerman, H.D.; Thomson, J.W.; Murray, K.J. Non-Hodgkin’s lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 1992, 23, 9–17.
    More